Sign In
Buy GALT
$2.35
-0.0700 (-2.89%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT
01:15pm, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ: GALT). Such inve
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are adv
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm
09:54pm, Monday, 29'th Dec 2025
LOS ANGELES--(BUSINESS WIRE)---- $GALT--GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm.
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened
04:00am, Thursday, 18'th Dec 2025
Galectin Therapeutics Inc. (NASDAQ: GALT - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.14 and traded as high as $
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data
08:42am, Thursday, 04'th Dec 2025
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis
02:44am, Wednesday, 26'th Nov 2025
Galectin Therapeutics targets MASH cirrhosis with belapectin, addressing a highly unmet need with clear mechanistic rationale and promising clinical data. GALT's NAVIGATE trial showed belapectin's 2 m
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
08:00am, Friday, 14'th Nov 2025
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and p
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
01:00pm, Friday, 12'th Sep 2025
Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Tuesday, 02'nd Sep 2025
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company mana
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypert
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
08:00am, Monday, 31'st Mar 2025
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
08:00am, Friday, 10'th Jan 2025
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line resu
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
10:29am, Friday, 20'th Dec 2024
On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cir
NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its globa
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
10:35am, Monday, 09'th Dec 2024
The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre
